Latest Regulatory T cell Stories
Results presented in poster presentation beginning today and in oral presentation Saturday, November 8, at 1:40 PM at Society for Immunotherapy of Cancer annual meeting. ANN ARBOR,
When faced with pathogens, the immune system summons a swarm of cells made up of soldiers and peacekeepers.
ORLANDO, Fla., March 26, 2014 /PRNewswire/ -- TNI BioTech, Inc.
ORLANDO, Fla., March 12, 2014 /PRNewswire/ -- TNI BioTech, Inc.
A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.
By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors.
- To swell, as grain or wood with water.